Home > Insider Trading > Filing (0001104659-16-108207)

Filing Details

Accession Number:: 0001104659-16-108207
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-03-29 12:00:08
Reporting Period:: 2016-03-29

Filing Date:: 2016-03-29
Accepted Time:: 2016-03-29 12:00:08
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1626971	Corvus Pharmaceuticals Inc.	CRVS	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1357522	A. Peter Thompson	C/O Corvus Pharmaceuticals, Inc. 863 Mitten Road, Suite 102 Burlingame CA 94010		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, $0.0001 Par Value	Acquisiton	2016-03-29	3,994,674	$0.00	3,994,674	No	4	C	Indirect	See Footnotes
Common Stock, $0.0001 Par Value	Acquisiton	2016-03-29	713,776	$0.00	4,708,450	No	4	C	Indirect	See Footnotes
Common Stock, $0.0001 Par Value	Acquisiton	2016-03-29	550,000	$15.00	5,258,450	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnotes
No	4	C	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Convertible Preferred Stock	Disposition	2016-03-29	3,994,674	$0.00	3,994,674	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2016-03-29	713,776	$0.00	713,776	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

The Series A Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis at the consummation of the Issuer's initial public offering.
These securities are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the sole general partner of OPI V, and OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisers Act of 1940, as amended, is the sole managing member of GP V. Samuel D. Isaly ("Isaly"), a natural person, is the managing member of, and holder of a controlling interest in, Advisors. By virtue of such relationships, GP V, Advisors and Isaly may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is an employee of Advisors.
Each of GP V, Advisors, Isaly and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
The expiration date is not relevant to the conversion of these securities.
OPI V purchased an additional 550,000 shares of the Issuer's common stock in connection with the Issuer's initial public offering at the offering price of $15.00 per share.